Edition:
India

Grifols SA (GRLSbn.MC)

GRLSbn.MC on Madrid SE C.A.T.S.

17.18EUR
19 Oct 2018
Change (% chg)

€-0.42 (-2.39%)
Prev Close
€17.60
Open
€17.60
Day's High
€17.64
Day's Low
€17.18
Volume
80,408
Avg. Vol
105,755
52-wk High
€21.30
52-wk Low
€16.36

Latest Key Developments (Source: Significant Developments)

Grifols Disagrees With UBS Report On Potential Impact Of FcRn Inhibitors
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Grifols SA ::SAYS DISAGREES WITH UBS REPORT CONCLUSIONS IN RELATION TO POTENTIAL IMPACT OF FCRN INHIBITORS ON CO'S IMMUNOGLOBULIN BUSINESS.SAYS REPORT IS BASED SOLELY ON PRELIMINARY CLINICAL STUDIES WITH LIMITED NUMBER OF PATIENTS, THUS RESULTS ARE NOT CONCLUSIVE.  Full Article

Grifols Says FDA Approves New Gamastan To Treat Patients Exposed To Hepatitis A And Measles
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Grifols SA ::FDA APPROVES A NEW FORMULATION OF GAMASTAN (IMMUNOGLOBULIN) TO TREAT PATIENTS EXPOSED TO HEPATITIS A AND MEASLES.GAMASTAN IS THE ONLY IMMUNOGLOBULIN APPROVED IN THE US MARKET FOR IMMEDIATE PROTECTION AGAINST HEPATITIS A AND MEASLES VIRUSES.  Full Article

Grifols H1 EBITDA Down 4.7 Pct At 614.2 Mln Euros YoY
Friday, 27 Jul 2018 

July 27 (Reuters) - Grifols SA ::H1 EBITDA 614.2 MILLION EUROS VERSUS 644.4 MILLION EUROS YEAR AGO.H1 NET REVENUE 2.12 BILLION EUROS VERSUS 2.19 BILLION EUROS YEAR AGO.H1 NET PROFIT 319.0 MILLION EUROS VERSUS 277.9 MILLION EUROS YEAR AGO.H1 RESEARCH AND DEVELOPMENT NET INVESTMENT 141.3 MILLION EUROS VERSUS 129.3 MILLION EUROS YEAR AGO.H1 ADJUSTED NET PROFIT 355.9 MILLION EUROS VERSUS 330.2 MILLION EUROS YEAR AGO.FINANCIAL RESULTS AND LOWER TAXES IN THE U.S. CONTRIBUTE TO A 15% INCREASE IN NET PROFIT.  Full Article

Grifols To Pay Gross Dividend Of 0.204 Euro per Share
Friday, 25 May 2018 

May 25 (Reuters) - Grifols SA ::TO PAY GROSS DIVIDEND OF 0.204 EUR PER SHARE AGAINST FY 2017.  Full Article

Grifols says FDA approves genetic test and EMA biological sealant
Friday, 17 Nov 2017 

Nov 17 (Reuters) - GRIFOLS SA ::GETS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR ITS NEW GENETIC TEST TO DETECT ALPHA-1 ANTITRYPSIN DEFICIENCY‍​.THE EUROPEAN MEDICINES AGENCY (EMA) APPROVES NEW PRODUCT, BIOLOGICAL SEALANT, TO USE IN SURGICAL OPERATIONS IN ADULTS.‍​.  Full Article

Grifols gets approval from US FDA for new product
Monday, 6 Nov 2017 

Nov 6 (Reuters) - GRIFOLS SA ::EARNS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR NEW PRODUCT FIBRIN SEALANT (HUMAN) COMPOSED OF TWO PLASMA PROTEINS AND INDICATED FOR SURGICAL USE IN ADULTS.‍​.  Full Article

Grifols 9-month net profit up 6.3 pct at 431.8 mln euros YoY
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - GRIFOLS SA ::9-MONTH NET PROFIT 431.8 MILLION EUROS VERSUS 406.1 MILLION EUROS YEAR AGO.9-MONTH NET SALES 3.25 BILLION EUROS VERSUS 2.95 BILLION EUROS YEAR AGO.9-MONTH EBITDA 960.9 MILLION EUROS VERSUS 842.9 MILLION EUROS YEAR AGO.  Full Article

Grifols approves interim dividend of 0.18 eur/shr
Monday, 30 Oct 2017 

Oct 30 (Reuters) - GRIFOLS SA ::APPROVES INTERIM DIVIDEND OF 0.18 EURO PER SHARE PAYABLE DECEMBER 5‍​.  Full Article

Spanish stocks - Factors to watch on Thursday

The following Spanish stocks may be affected by newspaper reports and other factors on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: